• Add this page to "Favorite pages"
  • Print the text(Open link in a new browser window)
Here begins the text.

Subcommittee on Cell and Gene Therapy Products Produced in vivo

Background

In recent years, the progress in the development of gene therapy has realized ex vivo gene therapy (in which genetically modified target tissues/cells once removed from the body and administered back to the patient), such as chimeric antigen receptor (CAR)-T cell therapy. Meanwhile, in vivo gene therapy (in which a gene delivery vector is directly administered to patients) is also being attempted to create CAR-T in vivo.
The subcommittee discusses points to consider in the development and evaluation of novel in vivo gene therapy, focusing on the target specificity of various gene modification tools, based on the clinical experience of CAR-T and other gene therapies.

 

Member List

Member List of the Subcommittee on Cell and Gene Therapy Products Produced in vivo

Past meetings

Date No. PressRelease Agenda/List of Handouts Minutes
December 6, 2023 4th mtg. PressRelease Agenda/List of Handouts Minutes
October 5, 2023 3rd mtg. PressRelease Agenda/List of Handouts Minutes
August 10, 2023 2nd mtg. PressRelease Agenda/List of Handouts Minutes
June 1, 2023 1st mtg. PressRelease Agenda/List of Handouts Minutes

JCN 3010005007409

Shin-Kasumigaseki Building, 3-3-2 Kasumigaseki,
Chiyoda-ku, Tokyo 100-0013 Japan

  • Contact us
  • Access/Map

Copyright (C) Pharmaceuticals and Medical Devices Agency, All Rights Reserved.